» Articles » PMID: 26299230

Race and Ethnicity Influences on Cardiovascular and Renal Events in Patients with Diabetes Mellitus

Overview
Journal Am Heart J
Date 2015 Aug 25
PMID 26299230
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of end-stage renal disease (ESRD) has been consistently shown to be higher among blacks and Hispanics compared to whites with unmeasured risk factors and access to care as suggested explanations. In a high-risk cohort with frequent protocol-directed follow-up, we evaluated the influence of race on cardiovascular (CV) outcomes and incidence of ESRD.

Methods: TREAT was a randomized, double-blind, placebo-controlled study. This secondary analysis focused on role of race on outcomes. TREAT enrolled 4,038 patients with type 2 diabetes, chronic kidney disease (estimated glomerular filtration rate 20-60 mL/min per 1.73 m(2)), and anemia (hemoglobin level ≤11 g/dL) treated with either darbepoetin alfa or placebo. We compared self-described black and Hispanic patients to white patients with regard to baseline characteristics and outcomes, including mortality, CV outcomes (myocardial infarction, stroke, heart failure, resuscitated sudden death, and coronary revascularization), and incident ESRD. Multivariate adjusted Cox models were developed for these outcomes.

Results: Black and Hispanic patients were younger, more likely women, had less prior CV disease, and higher blood pressure. During a mean follow-up of 2.4 years with comparable access to care, blacks and Hispanics had a greater risk of ESRD but a significant lower risk of myocardial infarction and coronary revascularization than whites. After adjusting for confounders, blacks remained at significantly greater risk of ESRD than whites (hazard ratio 1.53, 95% CI 1.26-1.85, P < .001), whereas this ESRD risk did not persist among Hispanics.

Conclusion: Despite similar access to care and lower CV event rates, the risk of ESRD was higher among blacks and Hispanics than whites. For blacks, but not Hispanics, this increase was independent of known attributable risk factors.

Citing Articles

Interventions for fatigue in people with kidney failure requiring dialysis.

Natale P, Ju A, Strippoli G, Craig J, Saglimbene V, Unruh M Cochrane Database Syst Rev. 2023; 8:CD013074.

PMID: 37651553 PMC: 10468823. DOI: 10.1002/14651858.CD013074.pub2.


Impact of end stage renal disease on the clinical outcomes of diabetics admitted for heart failure: Analysis of national inpatient sample.

Almani M, Zhang Y, Arshad M, Usman M, Ayub M J Cardiovasc Thorac Res. 2023; 15(1):37-43.

PMID: 37342662 PMC: 10278196. DOI: 10.34172/jcvtr.2023.30566.


Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Chung E, Palmer S, Saglimbene V, Craig J, Tonelli M, Strippoli G Cochrane Database Syst Rev. 2023; 2:CD010590.

PMID: 36791280 PMC: 9924302. DOI: 10.1002/14651858.CD010590.pub3.


Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease.

Khanijou V, Zafari N, Coughlan M, MacIsaac R, Ekinci E Diabetes Metab Res Rev. 2022; 38(6):e3556.

PMID: 35708187 PMC: 9541229. DOI: 10.1002/dmrr.3556.


Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.

van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R Clin Pharmacokinet. 2021; 61(3):439-450.

PMID: 34773606 PMC: 8891099. DOI: 10.1007/s40262-021-01082-2.